about
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndromeA glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study.Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Ethanol pharmacokinetics in neonates and infantsThe pharmacokinetics of taurolidine metabolites in healthy volunteers.Pharmacologic and clinical evaluation of posaconazole.Healthy volunteer registries and ethical research principles.The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis.Acid peptic diseases: pharmacological approach to treatment.Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.Cardiovascular protection to improve clinical outcomes after subarachnoid hemorrhage: is there a proven role?Prevalence of obstructive lung disease in HIV population: a cross sectional study.Potential for interactions between caspofungin and nelfinavir or rifampin.Experimental therapeutics: a paradigm for personalized medicine.Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patientsPharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting.The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers.Indinavir and rifabutin drug interactions in healthy volunteers.The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis.MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans.Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects.Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.Obstructive sleep apnea syndrome and postoperative complications: clinical use of the STOP-BANG questionnaire.Effect of aprepitant on the pharmacokinetics of intravenous midazolam.Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract.Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation.The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimusThe effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirinClinical pharmacology: a paradigm for individualized medicineBridging the therapeutic continuum of drug development, regulation and useAprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recoveryDevelopment of an abbreviated symptom score for the neonatal abstinence syndromeCould Postnatal Age-Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?
P50
Q24594941-E3BA6F9E-51E4-401D-8FCE-D82173740083Q33403643-966EA293-E1A8-44E6-8EE2-50BE8FC1DD7AQ33798286-7B115220-4C2C-4331-BC9C-3B9C4FAC1986Q34440525-A3715FFA-D878-4825-915B-A66B0F6850B6Q34613916-D4FA8229-489F-4EAF-B132-896CA60CD929Q37445943-04E8636B-B76D-4433-8ED7-781042B5680AQ37511947-1354B69B-A079-41D6-9AA6-EA1E8421862DQ37867004-D177565C-1B7E-4D7E-B6C8-5A0DE696D700Q37913063-20558F27-BD78-4455-9469-F1AE3D5D4F08Q37939894-96CE64B0-4A21-4CD0-9988-9A164234DB89Q38067298-651529E7-8A77-41CF-A6F8-D62A36DADA3BQ39988506-88C09408-1445-420B-AD92-861CBF9A4FB0Q40288945-A6A15700-77F3-4C9B-98C8-862E4BA6359BQ42316409-4538EF45-CCDF-484D-806B-3A6A15D0AD4EQ42358803-FE923392-5AC0-4631-81CE-E007AB74C893Q42635425-07A1C03B-FF19-44A5-BB8D-2219284CF071Q42992996-850E47DD-4016-41DC-AD1C-84BA5187E9D5Q43159242-1B91ECE9-853C-49F0-A4D7-0872FCEEFF7CQ43731322-31332A7D-EEAA-4078-BE27-FC9BD7FDF5DAQ44697438-0A8460F9-6D9A-4F6C-BE8B-8422D5828FB1Q44770185-320EE3C2-4734-4D67-A6DF-50ED7C2659A6Q45040968-A02BB333-E1E1-4CA8-B16D-8487CACD86AEQ45344338-D35B6ACD-2EB6-4630-9A4D-AC07B10D3E2DQ45805817-7190EBEF-203F-4872-87D6-1367ACB5F5ADQ46954383-3414A565-85B0-46B1-B659-FC73051D2AB5Q48231926-2217D3C9-76FE-4ABD-BF1C-1B7CF062A2D0Q48333205-8D5EE79D-8EF7-41EE-AA2F-E8C2669095D9Q48336139-85E2B448-6FB5-4938-A6F2-8BD0C9B1AA43Q48602084-6658CBBA-B81E-40DD-9862-C37BBF3CBC9FQ50487945-AA825555-248C-4418-BC19-9AF75E7AB0E8Q53664876-D55F0D52-9900-4D7F-8E69-B7FE0DB62FB0Q61314885-68EFD606-CC0B-40D6-8993-FDF997548FA7Q83990275-5C663CF2-5203-40B9-8D1F-16A0EC5DB220Q84240340-6C19F8B6-A46B-44D8-A5CF-6595946E604CQ87070366-3657A573-49E0-48EB-BEB7-A970FDD555C5Q87070378-0532413B-9630-40AF-A304-CF71C459DAC5Q89791774-59C914E8-5359-4BAD-8760-8500D3B3711FQ91683088-D4FF4CFA-FD17-4395-85A2-EE0FCA47CCBC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Walter K. Kraft
@ast
Walter K. Kraft
@en
Walter K. Kraft
@es
Walter K. Kraft
@nl
Walter K. Kraft
@sl
type
label
Walter K. Kraft
@ast
Walter K. Kraft
@en
Walter K. Kraft
@es
Walter K. Kraft
@nl
Walter K. Kraft
@sl
prefLabel
Walter K. Kraft
@ast
Walter K. Kraft
@en
Walter K. Kraft
@es
Walter K. Kraft
@nl
Walter K. Kraft
@sl
P106
P1153
7102138654
P21
P31
P496
0000-0002-5074-0141